Abhinav Gupta1, William Stokes1, Megan Eguchi2, Mohammad Hararah3, Arya Amini4, Adam Mueller1, Rustain Morgan5, Cathy Bradley6, David Raben1, Jessica McDermott7, Sana D Karam8. 1. Department of Radiation Oncology, University of Colorado, Denver, United States. 2. Department of Health Systems, Management, and Policy, Colorado School of Public Health, United States. Electronic address: MEGAN.EGUCHI@ucdenver.edu. 3. Department of Otolaryngology, University of Colorado, Denver, United States. 4. Department of Radiation Oncology, City of Hope Medical Center, United States. 5. Department of Radiology, University of Colorado, Denver, United States. 6. Department of Health Systems, Management, and Policy, Colorado School of Public Health, United States. 7. Department of Medicine, Division of Medical Oncology, University of Colorado, Denver, United States. 8. Department of Radiation Oncology, University of Colorado, Denver, United States. Electronic address: sana.karam@ucdenver.edu.
Abstract
OBJECTIVES: Studies have shown the utility of lipid-lowering agents in improving outcomes in various cancers. We aim to explore how statins affect overall survival and cancer specific survival in head and neck cancer patients using population-based datasets. PATIENTS AND METHODS: Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked dataset, we separated HNC patients into three groups: those with no hyperlipidemia (nH), those with hyperlipidemia and not taking a statin (HnS), and those with hyperlipidemia and taking a statin (H + S). Overall survival (OS) and cancer specific survival (CSS) were compared between the three groups based on disease subsite (oral cavity, oropharynx, and other) using Kaplan-Meier and multivariate Cox regression analysis (MVA), controlling for demographic, socioeconomic, staging, treatment, and comorbidity covariates. Using Pearson chi-square analysis, we also compared the incidence of cancer-related toxicity events. RESULTS: There were 495 nH, 567 HnS, and 530 H + S patients. H + S patients had superior OS and CSS (73.0, 81.2%) relative to nH (58.6, 69.1%) and HnS groups (61.7, 69.2%) (p < 0.01). On MVA, H + S patients showed improved OS (p < 0.01) and CSS (p = 0.04) compared to nH (HR = 1.64, 1.56) and HnS (HR = 1.40, 1.37). MVA stratified by subsite yielded similar results for oral cavity and oropharyngeal disease. Toxicity-related events did not differ significantly between the groups. CONCLUSION: HNC patients with hyperlipidemia and taking a statin demonstrated improved outcomes compared to nH and HnS patients, further supporting statins' role as a potential adjuvant anti-neoplastic agent in HNC. Further prospective studies to investigate the impact of statins on HNC outcomes are warranted.
OBJECTIVES: Studies have shown the utility of lipid-lowering agents in improving outcomes in various cancers. We aim to explore how statins affect overall survival and cancer specific survival in head and neck cancerpatients using population-based datasets. PATIENTS AND METHODS: Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked dataset, we separated HNC patients into three groups: those with no hyperlipidemia (nH), those with hyperlipidemia and not taking a statin (HnS), and those with hyperlipidemia and taking a statin (H + S). Overall survival (OS) and cancer specific survival (CSS) were compared between the three groups based on disease subsite (oral cavity, oropharynx, and other) using Kaplan-Meier and multivariate Cox regression analysis (MVA), controlling for demographic, socioeconomic, staging, treatment, and comorbidity covariates. Using Pearson chi-square analysis, we also compared the incidence of cancer-related toxicity events. RESULTS: There were 495 nH, 567 HnS, and 530 H + S patients. H + S patients had superior OS and CSS (73.0, 81.2%) relative to nH (58.6, 69.1%) and HnS groups (61.7, 69.2%) (p < 0.01). On MVA, H + S patients showed improved OS (p < 0.01) and CSS (p = 0.04) compared to nH (HR = 1.64, 1.56) and HnS (HR = 1.40, 1.37). MVA stratified by subsite yielded similar results for oral cavity and oropharyngeal disease. Toxicity-related events did not differ significantly between the groups. CONCLUSION: HNC patients with hyperlipidemia and taking a statin demonstrated improved outcomes compared to nH and HnS patients, further supporting statins' role as a potential adjuvant anti-neoplastic agent in HNC. Further prospective studies to investigate the impact of statins on HNC outcomes are warranted.
Authors: William A Stokes; Megan Eguchi; Arya Amini; Mohammad K Hararah; Ding Ding; Jessica D McDermott; Cathy J Bradley; Sana D Karam Journal: Oral Oncol Date: 2018-06-30 Impact factor: 5.337
Authors: Nicole L Lebo; Rebecca Griffiths; Stephen Hall; Jim Dimitroulakos; Stephanie Johnson-Obaseki Journal: Head Neck Date: 2018-06-22 Impact factor: 3.147
Authors: Yirong Zhu; Mark D Aupperlee; Yong Zhao; Ying Siow Tan; Erin L Kirk; Xuezheng Sun; Melissa A Troester; Richard C Schwartz; Sandra Z Haslam Journal: Oncotarget Date: 2016-12-13
Authors: Nima Daneshi; Mohammad Fararouei; Mohammad Mohammadianpanah; Mohammad Zare-Bandamiri; Somayeh Parvin; Mostafa Dianatinasab Journal: J Cancer Epidemiol Date: 2018-06-03
Authors: Kayla R Getz; Emily Bellile; Katie R Zarins; Cailey Rullman; Steven B Chinn; Jeremy M G Taylor; Laura S Rozek; Gregory T Wolf; Alison M Mondul Journal: Int J Cancer Date: 2020-12-15 Impact factor: 7.316
Authors: Dina Ezzat Mahmoud; Ahmed Hassan Ibrahim Faraag; Wael Mohamed Abu El-Wafa Journal: World J Microbiol Biotechnol Date: 2021-10-11 Impact factor: 3.312
Authors: Amy Dickinson; Mayank Saraswat; Stina Syrjänen; Tiialotta Tohmola; Robert Silén; Reija Randén-Brady; Timo Carpén; Jaana Hagström; Caj Haglund; Petri Mattila; Antti Mäkitie; Sakari Joenväärä; Suvi Silén Journal: PLoS One Date: 2020-06-15 Impact factor: 3.240
Authors: Kayla R Getz; Emily Bellile; Katie R Zarins; Steven B Chinn; Jeremy M G Taylor; Laura S Rozek; Gregory T Wolf; Alison M Mondul Journal: Head Neck Date: 2022-03-25 Impact factor: 3.821